Published in Curr Pharm Des on January 01, 2005
Malignant perinatal variant of long-QT syndrome caused by a profoundly dysfunctional cardiac sodium channel. Circ Arrhythm Electrophysiol (2008) 1.53
Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet (2014) 1.27
Pharmacogenetics and anti-arrhythmic drug therapy: a theoretical investigation. Am J Physiol Heart Circ Physiol (2006) 1.23
Effects of L-type Ca2+ channel antagonism on ventricular arrhythmogenesis in murine hearts containing a modification in the Scn5a gene modelling human long QT syndrome 3. J Physiol (2006) 1.05
Effects of flecainide and quinidine on arrhythmogenic properties of Scn5a+/Delta murine hearts modelling long QT syndrome 3. J Physiol (2006) 0.98
Abnormal repolarization as the basis for late potentials and fractionated electrograms recorded from epicardium in experimental models of Brugada syndrome. J Am Coll Cardiol (2014) 0.92
A rare association of long QT syndrome and syndactyly: Timothy syndrome (LQT 8). Clin Res Cardiol (2011) 0.89
Mechanisms of drug-induced proarrhythmia in clinical practice. World J Cardiol (2013) 0.83
A new hERG allosteric modulator rescues genetic and drug-induced long-QT syndrome phenotypes in cardiomyocytes from isogenic pairs of patient induced pluripotent stem cells. EMBO Mol Med (2016) 0.81
Partially dominant mutant channel defect corresponding with intermediate LQT2 phenotype. Pacing Clin Electrophysiol (2011) 0.76
Drug Therapy For Preventing Ventricular Arrhythmia In Brugada syndrome: Do We Have The Answers Yet? Indian Pacing Electrophysiol J (2013) 0.75
Antiarrhythmic Drug Therapy to Avoid Implantable Cardioverter Defibrillator Shocks. Arrhythm Electrophysiol Rev (2016) 0.75
Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol (1992) 12.18
A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell (1995) 11.62
Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature (1996) 9.77
K(V)LQT1 and lsK (minK) proteins associate to form the I(Ks) cardiac potassium current. Nature (1996) 8.63
Prolongation of the QT interval and the sudden infant death syndrome. N Engl J Med (1998) 8.49
SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell (1995) 7.73
Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation (2000) 7.50
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26
Risk stratification in the long-QT syndrome. N Engl J Med (2003) 7.25
KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science (2003) 6.60
Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature (2003) 5.94
Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation (2001) 5.68
MiRP1 forms IKr potassium channels with HERG and is associated with cardiac arrhythmia. Cell (1999) 5.49
Cellular basis for the electrocardiographic J wave. Circulation (1996) 5.25
Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation (2000) 5.09
Cellular basis for the Brugada syndrome and other mechanisms of arrhythmogenesis associated with ST-segment elevation. Circulation (1999) 5.04
Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation (1995) 4.48
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
Mutations in Kir2.1 cause the developmental and episodic electrical phenotypes of Andersen's syndrome. Cell (2001) 4.25
Cellular basis for the normal T wave and the electrocardiographic manifestations of the long-QT syndrome. Circulation (1998) 4.13
Sodium channel blockers identify risk for sudden death in patients with ST-segment elevation and right bundle branch block but structurally normal hearts. Circulation (2000) 3.99
ECG T-wave patterns in genetically distinct forms of the hereditary long QT syndrome. Circulation (1995) 3.79
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
The long Q-T syndrome. Am Heart J (1975) 3.75
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
The M cell: its contribution to the ECG and to normal and abnormal electrical function of the heart. J Cardiovasc Electrophysiol (1999) 3.57
Influence of genotype on the clinical course of the long-QT syndrome. International Long-QT Syndrome Registry Research Group. N Engl J Med (1998) 3.41
Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science (1991) 3.38
Mutations of the cardiac ryanodine receptor (RyR2) gene in familial polymorphic ventricular tachycardia. Circulation (2001) 3.34
Natural history of Brugada syndrome: insights for risk stratification and management. Circulation (2002) 3.10
Heterogeneity within the ventricular wall. Electrophysiology and pharmacology of epicardial, endocardial, and M cells. Circ Res (1991) 3.07
Spectrum of ST-T-wave patterns and repolarization parameters in congenital long-QT syndrome: ECG findings identify genotypes. Circulation (2000) 2.95
Postmortem molecular analysis of SCN5A defects in sudden infant death syndrome. JAMA (2001) 2.89
"Brugada" syndrome: clinical data and suggested pathophysiological mechanism. Circulation (1999) 2.83
Cardiac conduction defects associate with mutations in SCN5A. Nat Genet (1999) 2.73
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation (1996) 2.70
Right bundle-branch block and ST-segment elevation in leads V1 through V3: a marker for sudden death in patients without demonstrable structural heart disease. Circulation (1998) 2.67
The Brugada syndrome: clinical, electrophysiologic and genetic aspects. J Am Coll Cardiol (1999) 2.56
Transient outward current prominent in canine ventricular epicardium but not endocardium. Circ Res (1988) 2.49
Differential effects of beta-adrenergic agonists and antagonists in LQT1, LQT2 and LQT3 models of the long QT syndrome. J Am Coll Cardiol (2000) 2.42
Autonomic and antiarrhythmic drug modulation of ST segment elevation in patients with Brugada syndrome. J Am Coll Cardiol (1996) 2.42
A new oral therapy for long QT syndrome: long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol (2003) 2.28
Larger late sodium conductance in M cells contributes to electrical heterogeneity in canine ventricle. Am J Physiol Heart Circ Physiol (2001) 2.27
Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation (1997) 2.20
Effects of electrophysiologic-guided therapy with Class IA antiarrhythmic drugs on the long-term outcome of patients with idiopathic ventricular fibrillation with or without the Brugada syndrome. J Cardiovasc Electrophysiol (1999) 2.20
Dynamic changes of 12-lead electrocardiograms in a patient with Brugada syndrome. J Cardiovasc Electrophysiol (1998) 2.19
Gene-specific response of dynamic ventricular repolarization to sympathetic stimulation in LQT1, LQT2 and LQT3 forms of congenital long QT syndrome. Eur Heart J (2002) 2.17
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Transient outward current in human ventricular myocytes of subepicardial and subendocardial origin. Circ Res (1994) 2.16
Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res (2003) 2.14
Effect of sodium channel blockers on ST segment, QRS duration, and corrected QT interval in patients with Brugada syndrome. J Cardiovasc Electrophysiol (2000) 2.08
Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm (2004) 2.05
A molecular link between the sudden infant death syndrome and the long-QT syndrome. N Engl J Med (2000) 2.02
Epinephrine-induced QT interval prolongation: a gene-specific paradoxical response in congenital long QT syndrome. Mayo Clin Proc (2002) 1.95
Determinants of sudden cardiac death in individuals with the electrocardiographic pattern of Brugada syndrome and no previous cardiac arrest. Circulation (2003) 1.92
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Arrhythmogenic marker for the sudden unexplained death syndrome in Thai men. Circulation (1997) 1.88
Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation (1996) 1.86
The long QT syndrome: a prospective international study. Circulation (1985) 1.77
KVLQT1 C-terminal missense mutation causes a forme fruste long-QT syndrome. Circulation (1997) 1.76
The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge. Circulation (2000) 1.72
Regional variations in action potentials and transient outward current in myocytes isolated from rabbit left ventricle. J Physiol (1991) 1.67
Electrophysiologic characteristics and implications of induced ventricular fibrillation in symptomatic patients with Brugada syndrome. J Am Coll Cardiol (2002) 1.63
Cellular and ionic basis for T-wave alternans under long-QT conditions. Circulation (1999) 1.55
Overdose of cyclic antidepressants and the Brugada syndrome. N Engl J Med (2002) 1.54
Brugada syndrome: 1992-2002: a historical perspective. J Am Coll Cardiol (2003) 1.54
Brugada syndrome: a decade of progress. Circ Res (2002) 1.54
Auditory stimuli as a trigger for arrhythmic events differentiate HERG-related (LQTS2) patients from KVLQT1-related patients (LQTS1). J Am Coll Cardiol (1999) 1.54
Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome? Circulation (2000) 1.46
Exercise stress test amplifies genotype-phenotype correlation in the LQT1 and LQT2 forms of the long-QT syndrome. Circulation (2003) 1.43
Effects of a K(+) channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation (2000) 1.43
Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation (1993) 1.38
Epinephrine unmasks latent mutation carriers with LQT1 form of congenital long-QT syndrome. J Am Coll Cardiol (2003) 1.35
Quinidine induced electrocardiographic normalization in two patients with Brugada syndrome. Pacing Clin Electrophysiol (2001) 1.33
Swimming, a gene-specific arrhythmogenic trigger for inherited long QT syndrome. Mayo Clin Proc (1999) 1.32
Cellular basis for long QT, transmural dispersion of repolarization, and torsade de pointes in the long QT syndrome. J Electrocardiol (1999) 1.31
Comparison of clinical and genetic variables of cardiac events associated with loud noise versus swimming among subjects with the long QT syndrome. Am J Cardiol (1999) 1.25
Differences in transient outward currents of feline endocardial and epicardial myocytes. Circ Res (1990) 1.23
Early afterdepolarizations induced by isoproterenol in patients with congenital long QT syndrome. Circulation (1991) 1.20
Hydroquinidine therapy in Brugada syndrome. J Am Coll Cardiol (2004) 1.19
Infant case with a malignant form of Brugada syndrome. J Cardiovasc Electrophysiol (2000) 1.19
Prevention of ventricular fibrillation by cilostazol, an oral phosphodiesterase inhibitor, in a patient with Brugada syndrome. J Cardiovasc Electrophysiol (2002) 1.17
Sympathetic stimulation produces a greater increase in both transmural and spatial dispersion of repolarization in LQT1 than LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol (2001) 1.12
Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. J Am Coll Cardiol (1995) 1.10
Improvement of repolarization abnormalities by a K+ channel opener in the LQT1 form of congenital long-QT syndrome. Circulation (1998) 1.08
Ventricular arrhythmia induced by sodium channel blocker in patients with Brugada syndrome. J Am Coll Cardiol (2003) 1.05
Differential effects of beta-blockade on dispersion of repolarization in the absence and presence of sympathetic stimulation between the LQT1 and LQT2 forms of congenital long QT syndrome. J Am Coll Cardiol (2002) 1.02
The long QT interval syndrome. A Rosetta stone for sympathetic related ventricular tachyarrhythmias. Circulation (1991) 1.02
Body surface distribution and response to drugs of ST segment elevation in Brugada syndrome: clinical implication of eighty-seven-lead body surface potential mapping and its application to twelve-lead electrocardiograms. J Cardiovasc Electrophysiol (2000) 1.01
Role of heme oxygenase-1 in cardiovascular function. Curr Pharm Des (2003) 1.00
Characteristics of patients with right bundle branch block and ST-segment elevation in right precordial leads. Idiopathic Ventricular Fibrillation Investigators. Am J Cardiol (1996) 0.99
Pleiotropic effects of cytokines on acute myocardial infarction: G-CSF as a novel therapy for acute myocardial infarction. Curr Pharm Des (2003) 0.87
Catecholamines in children with congenital long QT syndrome and Brugada syndrome. J Electrocardiol (2001) 0.85
Frequency-dependent electrophysiologic properties of ventricular repolarization in patients with congenital long QT syndrome. J Am Coll Cardiol (1996) 0.84
Effects of sympathetic stimulation on various repolarization indices in the congenital long QT syndrome. Ann Noninvasive Electrocardiol (2002) 0.84
Hypertension and concurrent arrhythmias. Curr Pharm Des (2003) 0.79
An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm (2009) 4.99
Proposed diagnostic criteria for the Brugada syndrome: consensus report. Circulation (2002) 3.76
Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation (2003) 3.68
Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine. Circulation (2007) 2.90
Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm (2010) 2.79
Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation (2003) 2.74
The response of the QT interval to the brief tachycardia provoked by standing: a bedside test for diagnosing long QT syndrome. J Am Coll Cardiol (2010) 2.56
Electromechanical coupling in patients with the short QT syndrome: further insights into the mechanoelectrical hypothesis of the U wave. Heart Rhythm (2007) 2.44
Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol (2008) 2.42
Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med (2008) 2.38
Transient outward current (I(to)) gain-of-function mutations in the KCND3-encoded Kv4.3 potassium channel and Brugada syndrome. Heart Rhythm (2011) 2.26
Fever-induced Brugada pattern: how common is it and what does it mean? Heart Rhythm (2013) 2.25
Ionic and cellular basis for the predominance of the Brugada syndrome phenotype in males. Circulation (2002) 2.23
The homeodomain transcription factor Irx5 establishes the mouse cardiac ventricular repolarization gradient. Cell (2005) 2.19
Is there a significant transmural gradient in repolarization time in the intact heart? Cellular basis of the T wave: a century of controversy. Circ Arrhythm Electrophysiol (2009) 2.16
Genetic and biophysical basis of sudden unexplained nocturnal death syndrome (SUNDS), a disease allelic to Brugada syndrome. Hum Mol Genet (2002) 2.16
Transmural heterogeneity of calcium activity and mechanical function in the canine left ventricle. Am J Physiol Heart Circ Physiol (2003) 2.12
Role of sodium and calcium channel block in unmasking the Brugada syndrome. Heart Rhythm (2004) 2.07
Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol (2004) 2.05
Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm (2006) 2.03
Atrial-selective inhibition of sodium-channel current by Wenxin Keli is effective in suppressing atrial fibrillation. Heart Rhythm (2011) 2.01
A transient outward potassium current activator recapitulates the electrocardiographic manifestations of Brugada syndrome. Cardiovasc Res (2008) 2.01
Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci (2003) 1.97
Atrial-selective effects of chronic amiodarone in the management of atrial fibrillation. Heart Rhythm (2008) 1.96
Disease characterization using LQTS-specific induced pluripotent stem cells. Cardiovasc Res (2012) 1.95
Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Heart Rhythm (2006) 1.91
Long-term follow-up of individuals with the electrocardiographic pattern of right bundle-branch block and ST-segment elevation in precordial leads V1 to V3. Circulation (2002) 1.91
Malignant entity of idiopathic ventricular fibrillation and polymorphic ventricular tachycardia initiated by premature extrasystoles originating from the right ventricular outflow tract. J Am Coll Cardiol (2005) 1.88
Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther (2004) 1.88
Molecular genetic and functional association of Brugada and early repolarization syndromes with S422L missense mutation in KCNJ8. Heart Rhythm (2011) 1.87
A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet (2009) 1.87
Short QT syndrome: pharmacological treatment. J Am Coll Cardiol (2004) 1.87
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death. Nat Genet (2013) 1.86
Amplified transmural dispersion of repolarization as the basis for arrhythmogenesis in a canine ventricular-wedge model of short-QT syndrome. Circulation (2004) 1.86
Cellular basis for the monophasic action potential. Which electrode is the recording electrode? Cardiovasc Res (2004) 1.85
Unique topographical distribution of M cells underlies reentrant mechanism of torsade de pointes in the long-QT syndrome. Circulation (2002) 1.84
Intravenous drug challenge using flecainide and ajmaline in patients with Brugada syndrome. Heart Rhythm (2005) 1.83
Tpeak-Tend and Tpeak-Tend dispersion as risk factors for ventricular tachycardia/ventricular fibrillation in patients with the Brugada syndrome. J Am Coll Cardiol (2006) 1.78
The pathophysiological mechanism underlying Brugada syndrome: depolarization versus repolarization. J Mol Cell Cardiol (2010) 1.78
Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations. J Cardiovasc Electrophysiol (2009) 1.78
Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol (2005) 1.74
Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm (2006) 1.74
Effect of sodium-channel blockade on early repolarization in inferior/lateral leads in patients with idiopathic ventricular fibrillation and Brugada syndrome. Heart Rhythm (2011) 1.71
Cellular basis for arrhythmogenesis in an experimental model of the SQT1 form of the short QT syndrome. Heart Rhythm (2008) 1.69
Phenotypic characterization of a large European family with Brugada syndrome displaying a sudden unexpected death syndrome mutation in SCN5A:. J Cardiovasc Electrophysiol (2004) 1.69
Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling. Circulation (2012) 1.65
Mechanisms of enhanced beta-adrenergic reserve from cardiac resynchronization therapy. Circulation (2009) 1.63
Provocation of sudden heart rate oscillation with adenosine exposes abnormal QT responses in patients with long QT syndrome: a bedside test for diagnosing long QT syndrome. Eur Heart J (2005) 1.61
Cyclic GMP/PKG-dependent inhibition of TRPC6 channel activity and expression negatively regulates cardiomyocyte NFAT activation Novel mechanism of cardiac stress modulation by PDE5 inhibition. J Mol Cell Cardiol (2009) 1.60
Late-phase 3 EAD. A unique mechanism contributing to initiation of atrial fibrillation. Pacing Clin Electrophysiol (2006) 1.60
Brugada-like syndrome in infancy presenting with rapid ventricular tachycardia and intraventricular conduction delay. Circulation (2011) 1.60
A novel mutation in the HCN4 gene causes symptomatic sinus bradycardia in Moroccan Jews. J Cardiovasc Electrophysiol (2010) 1.60
Early repolarization syndrome: a decade of progress. J Electrocardiol (2013) 1.59
AZD1305 exerts atrial predominant electrophysiological actions and is effective in suppressing atrial fibrillation and preventing its reinduction in the dog. J Cardiovasc Pharmacol (2010) 1.57
Genetic and biophysical basis for bupivacaine-induced ST segment elevation and VT/VF. Anesthesia unmasked Brugada syndrome. Heart Rhythm (2006) 1.56
Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations. J Am Coll Cardiol (2011) 1.55
Transmembrane action potential heterogeneity in the canine isolated arterially perfused right atrium: effect of IKr and IKur/Ito block. Am J Physiol Heart Circ Physiol (2004) 1.53
Mutation site-specific differences in arrhythmic risk and sensitivity to sympathetic stimulation in the LQT1 form of congenital long QT syndrome: multicenter study in Japan. J Am Coll Cardiol (2004) 1.51
Cisapride-induced transmural dispersion of repolarization and torsade de pointes in the canine left ventricular wedge preparation during epicardial stimulation. Circulation (2003) 1.51
Cellular basis for atrial fibrillation in an experimental model of short QT1: implications for a pharmacological approach to therapy. Heart Rhythm (2009) 1.51
Cardiac resynchronization therapy corrects dyssynchrony-induced regional gene expression changes on a genomic level. Circ Cardiovasc Genet (2009) 1.51
Cellular mechanisms underlying the development of catecholaminergic ventricular tachycardia. Circulation (2005) 1.50
Functional expression of "cardiac-type" Nav1.5 sodium channel in canine intracardiac ganglia. Heart Rhythm (2006) 1.50
Fever and Brugada syndrome. Pacing Clin Electrophysiol (2002) 1.48
Significance of non-type 1 anterior early repolarization in patients with inferolateral early repolarization syndrome. J Am Coll Cardiol (2013) 1.47
Torsades de pointes following acute myocardial infarction: evidence for a deadly link with a common genetic variant. Heart Rhythm (2012) 1.46
Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations. Heart Rhythm (2008) 1.46
Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene. Heart Rhythm (2011) 1.46
Resolving the M-cell debate: why and how. Heart Rhythm (2011) 1.45
Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations. Heart Rhythm (2011) 1.44
Subcellular structures and function of myocytes impaired during heart failure are restored by cardiac resynchronization therapy. Circ Res (2012) 1.44
A novel rare variant in SCN1Bb linked to Brugada syndrome and SIDS by combined modulation of Na(v)1.5 and K(v)4.3 channel currents. Heart Rhythm (2011) 1.43
Impact of left ventricular diastolic dysfunction on outcome of catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. Circ J (2014) 1.43
KCNE2 modulation of Kv4.3 current and its potential role in fatal rhythm disorders. Heart Rhythm (2009) 1.43
Is a narrow and tall QRS complex an ECG marker for sudden death? Heart Rhythm (2008) 1.42
Epicardial activation of left ventricular wall prolongs QT interval and transmural dispersion of repolarization: implications for biventricular pacing. Circulation (2004) 1.39
Mode of onset of ventricular fibrillation in patients with early repolarization pattern vs. Brugada syndrome. Eur Heart J (2009) 1.38
Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J (2011) 1.37
Autonomic aspects of arrhythmogenesis: the enduring and the new. Curr Opin Cardiol (2004) 1.35
Cellular and subcellular alternans in the canine left ventricle. Am J Physiol Heart Circ Physiol (2007) 1.32
Can inhibition of IKur promote atrial fibrillation? Heart Rhythm (2008) 1.31
Cellular basis for ST-segment changes observed during ischemia. J Electrocardiol (2003) 1.31
Sudden cardiac death secondary to antidepressant and antipsychotic drugs. Expert Opin Drug Saf (2008) 1.30
Occurrence of "J waves" in 12-lead ECG as a marker of acute ischemia and their cellular basis. Pacing Clin Electrophysiol (2007) 1.28
Novel calmodulin mutations associated with congenital arrhythmia susceptibility. Circ Cardiovasc Genet (2014) 1.27
Gain of function in IKs secondary to a mutation in KCNE5 associated with atrial fibrillation. Heart Rhythm (2008) 1.27
Synergistic effect of the combination of ranolazine and dronedarone to suppress atrial fibrillation. J Am Coll Cardiol (2010) 1.27
New developments in atrial antiarrhythmic drug therapy. Nat Rev Cardiol (2010) 1.27
Cellular basis for the electrocardiographic and arrhythmic manifestations of Timothy syndrome: effects of ranolazine. Heart Rhythm (2007) 1.27
Mechanisms of disease: ion channel remodeling in the failing ventricle. Nat Clin Pract Cardiovasc Med (2008) 1.24
Does Tpeak-Tend provide an index of transmural dispersion of repolarization? Heart Rhythm (2007) 1.23
Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). PLoS One (2012) 1.23
Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol (2010) 1.21
The role of local voltage potentials in outflow tract ectopy. Europace (2010) 1.20
Atrial-selective sodium channel blockers: do they exist? J Cardiovasc Pharmacol (2008) 1.18
Low-frequency oscillation of sympathetic nerve activity decreases during development of tilt-induced syncope preceding sympathetic withdrawal and bradycardia. Am J Physiol Heart Circ Physiol (2005) 1.17